Status:
RECRUITING
Towards the Validation of a New Blood Biomarker for the Early Diagnosis of Parkinson's Disease
Lead Sponsor:
University Hospital, Grenoble
Collaborating Sponsors:
Grenoble Institut des Neurosciences
Conditions:
Parkinson Disease
Eligibility:
All Genders
18+ years
Brief Summary
The investigators have recently discovered a metabolic biomarker which predicts Parkinson's disease (PD) at the early stages in patients and in animal models. The aim of BIOPARK is to investigate how ...
Detailed Description
Parkinson's disease (PD) affects more than 7 million people worldwide and represents a growing health and socio-economic burden. It is an incurable neurodegenerative disease, and the search for biomar...
Eligibility Criteria
Inclusion
- Patients with de novo Parkinson's disease, without dopaminergic treatment
- Patients with advanced Parkinson's disease (\> 5years) with dopaminergic treatment
- Patients with multiple system atrophy
Exclusion
- Patients with deep brain stimulation
- Other neurodegenerative diseases
- patients protected by french law (pregnant or lactating women, prisoners, ...)
Key Trial Info
Start Date :
October 13 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05385315
Start Date
October 13 2022
End Date
December 31 2025
Last Update
December 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Grenoble Alpes
Grenoble, France, 38043